

# Eosinophilic Esophagitis 2020

Leonard Weinstock, MD  
Associate Professor of Clinical Medicine  
Washington University School of Medicine  
St. Louis, Missouri

# Disclosures

Off-label use of medications:  
No FDA-approved EoE Rx

Medical adviser: MC Science  
Speakers bureau: Salix, Takeda

# Teaching Points



- What is the history of this disease and how does this reflect on general society?
- How is EoE recognized by history, risk factors, biopsy and endoscopy?
- How can EoE be treated?
- What role does the PCP/Integrative physician play?

# Classic Case: 20 y.o. WM

- 1 yr dysphagia – intermittent, solids, dry food, sticks in mid to upper chest
- Spastic chest pain eating apples & carrots
- PMH: seasonal allergies; asthma as child
- FHx: F - dysphagia; S - asthma

# Classic Case at 10:30 PM:

“Hey Dr. W. we got a food bolus”



“Doc, I thought it would pass like it did 6 other times”

# The Eosinophil



Hx: Paul Ehrlich 1879

Structure:

Bilobed nuclei


Cytoplasm filled w  
>200 large granules

Enzymes & proteins  
w different functions  
(known & unknown)




# What Makes Eos Evil?

- Genes
- Allergies
- Mast cells
- Acid reflux



# What Makes Eos Evil? Genes

- EoE assoc. with variants at chromosome 5q22 encompassing *TSLP* and *WDR36* (rs3806932). *TSLP* overexpressed in esoph Bx in EoE vs. controls.
- Esophageal FK506-binding protein-5 (*FKBP51*) mRNA levels increased in steroid responders. This gene activates IL-6.
- Upregulated miR-21 & miR-223 and down-regulated miR-375 strongly correlated w esoph eos levels.






# What Makes Eos Evil? Allergies

- Mouse models show IL-5 (IP) and IL-13 (IT) induced EoE ... importance of allergens that caused disease by IL's
- Peds Bx study measuring mRNA expression of interferon, IL (4,5,13), eotaxin (1,2,3) & RANTES.

Data suggests IL-5 selective TH2 response, with a possible TH1 component.



# EoE and Food Allergies

## Why More Common Now?

- Freq. antibiotics → altered immunity & gut flora
- Increased dietary exposure in infancy & youth
- Acute GI infections trigger chronic systemic diseases via SIBO, inflam., autoimmunity, etc.
  - 75 million cases/yr
  - “Slow vs fast food”
- Increased intestinal permeability introduces larger antigens resulting in increased eos & MCs
- Increase in ileal lymphoid follicles and interaction w food antigens & bacteria

# What Makes Eos Evil? MCs


N=25 children w EoE vs. 22 GERD vs. 22 controls.  
Eos & MC counted (tryptase stain).

MC activation status by IgE stain and EM

EoE vs. GERD eos counts ( $55 \pm 28$  vs.  $6.9 \pm 10$ ,  $p < .0001$ )  
& MC counts ( $26.3 \pm 12.7$  vs.  $7.8 \pm 8.9$ ,  $p < .0001$ )

24/25 EoE pts contained IgE-bearing cells compared to  
9/22 GERD Bx ( $p < 0.001$ )

EM confirmed intraepithelial MCs and changes in  
cytoplasmic granules indicative of MC and  
eosinophil activation. Evidence for MC-mediated  
hypersensitivity



# What Makes Eos Evil? MCs

N = 93 children with EoE

Bx stained for tryptase and eval for degran. MCs

Study of “Histologic Inactive EoE with Sx” defined as “<15 hpf with continued dysphagia”, Persistent Endoscopic EoE (vs. Controls)


HI-EoE w Sx: 17 MC (vs. 8)

Persistent Endo EoE: 20 (vs. 13)

Degranulated MCs 8 (vs. 5)


MC/hpf – predicted furrows and rings

Low MC/hpf predicted clin. remiss.



# What Makes Eos Evil? Acid

- N = 60 EoE vs 60 GERD vs 60 Controls
- Impedance-pH monitor – evaluation of:
  - Post-reflux swallow induced peristaltic wave
  - Mean impedance
  - 24 hr pH
- PPI response diagnosed by improved Bx
- Results: EoE vs controls – more reflux and less post-reflux waves
- Low impedance predicted poor PPI response






# History of EoE

- **1978** – “Eosinophilic esophagitis in a pt w achalasia”
- **1982** – “Intraepithelial eosinophils assoc w acid reflux”
- **1993** – “Esophageal eosinophilia w dysphagia, a new entity”
- **2003** – “Natural Hx of 30 adult pts w EoE”

1990

2020


My first case and longest follow up



# Prevalence and Character of Dysphagia in USA

- Survey 31,129 adults
- 16% experienced dysphagia (one in six)
- 92% w/i last week, 16% severe
- 51% sought medical care
- Groups likely to seek care included:
  - Elderly, males, insured, severe Sx
- Co-morbid diagnoses reported
  - GERD 30%
  - EoE 8%
  - Stricture 5%

# Prevalence of EOE



➤ 2014 Prevalence: 57/100K (men 115/100K)

Straumann et al. J All Clin Immunol 2005

Dillon et al. Clin Gastro Hepatol 2014

# Clinical Presentation & Biopsies


- Males 75%; ages 36-42 in adults
- Allergies very common, Asthma 50%,
- Food allergies 10-30%
- Positive family history of EoE in 10%
- Peripheral eosinophilia 5 – 50%
- Increased IgE in 40-73%
- >15 Eos/hpf; yield – highest in upper and distal esophagus but can see wide variations
- Positive gastric biopsy in 10%



# EoE Sx: Adults vs Children

- Trouble swallowing – Adults and **Children**
- Food impaction – Adults
- Heartburn – Adults
- Nausea – **Children**
- Abdominal pain – **Children**

# Pathophysiology of EoE



# EREFS Score

Edema, Rings, Exudates, Furrows, & Strictures



# Natural History: Stenosis

- Retrospective Netherland study from 1996 – 2015 – N = 721
- Inflammatory to Fibrostenotic Path
- With each yr of symptoms w/o Dx, stricture risk increased by 9%

# Natural History: Seasonal?

- 18 studies with 17K pts
- No relationship for food bolus or diagnosis of EoE
- (sad finding for GI docs)



# Therapies – the 3 D's

Dilatation

Drugs

Diet

# Dilatation

- Start small
- Go slow
- Steroids first?
- Balloon vs. Bougie
- Characteristic tear pattern
- 1% perforation risk



# Dilations as Monotherapy (?)

- 30 adults (73% men), mean follow-up 7.2 yrs
- No treatment other than prn esophageal dilatation
- Dysphagia
  - increased: 7
  - stable: 11
  - improved: 11
- Only 11 patients required dilation
  - 7 single dilation and 4 repeated dilation
- Symptoms most severe in those with blood eosinophilia or pronounced endoscopic changes
- No malignant potential reported to date

# Therapies – the 3 D's

Dilatation

Drugs

- Topical steroids
  - Fluticasone
  - Budesonide
- PPI – “PPI-REE”
- Other drugs
- Biologicals

Diet

# Steroids

High- vs Low-Dose Swallowed Topical Steroids for Maintenance Rx

Multicenter retrospective study

N= 82 pts with EoE in histological remission on varying doses of swallowed corticosteroid therapy (SCT)

Followed for a median of 2.2 yrs, data from 217 endoscopy visits.

Relapse occurred in 67% of patients.



# Steroids

Rates comparable w low-dose (<0.5 mg/day; n=58) and high-dose (>0.5 mg/day; n=24) SCT (72% vs 54%, respectively).


Histological relapse occurred earlier with low-dose SCT (1.0 vs 1.8 years;  $P = .030$ ).

Regardless of SCT, histological relapse occurs frequently in EoE, with relapse developing later in those on higher doses without an increase in side effects.

Overall advantages of high-dose SCT appear small.

# Relapse after Steroid Monotherapy

Eosinophils (n/hpf)



*Liacouras et al, Clin Gastroenterol Hepatol 2005; 3: 1198*

# Recurrence of EoE after Cessation of Medicines

N=58 EoE w histo response entered into F/U phase; Bx at relapse or after 1 yr

- 33/58 (57%) developed Sx before 1 yr
- Median time 244 d but 130 d in those that relapsed before 1 yr
- 78% histological relapse
- Control of inflm reduced dilatations by 65%

# Inhaler Tricks

- Fluticasone 4 puffs (220 µg/puff)
- Twice daily, after breakfast and dinner
- Duration: 6 weeks
- Ensure delivery to esophagus (rather than lung) by removing the spacer
- Inspire deeply, depress the inhaler, and swallow the aerosol
- Rinse mouth with water and avoid food and drink for 2–3 hours

# Role of PPI's in EoE

The EDP differentiated patients with EoE from control subjects with 100% accuracy among the 4 clinical sites.

Bioinformatics analysis revealed largely overlapping transcriptomes between pts with PPI-REE and those with EoE, including genes for eosinophil chemotaxis (eotaxin 3, *CCL26*), barrier molecules (desmoglein 1, *DSG1*), tissue remodeling (periostin, *POSTN*), **and mast cells** (carboxypeptidase A, *CPA3*).

# Role of PPI's in EoE

PPI monotherapy alone almost completely reversed the allergic inflammatory transcriptome of pts with PPI-REE.

Wen et al identified a set of candidate genes to differentiate pts with EoE from those with PPI-REE before Rx



# Other Drugs in EoE

Azathioprine – potential help for refractory EoE disease

Cromolyn - No

Monteleukast – No

Infliximab - No

# Future Steroids in EoE

TAK-721 – budesonide oral suspension


APT-1011 – fluticasone disintegrating tablet

# Biological Drugs in EoE

In future:

- Dupilumab weekly SC injection – phase 3: 69% reduction in EoE. Indications steroid refractory, multiple allergy co-morbidities
- Antolimab – IV, Siglec-8 monoclonal antibody
- Etrasimod oral, highly selective, sphingosin 1-phosphate receptor modulator

# Integrative approach to EoE



# Therapies – the 3 D's Plus\*\*\*

Dilatation

Drugs

Diet

Six food and variations

Allergy directed

2-4-6 FOOD

(milk and gluten are worst)

Immuno-Rx – desens., MC Rx, LDN...

# Food Allergy and Intolerance

- Increasing prevalence of food allergies:
  - 8% of kids age 1 - 3
  - 4% of adults
- Most common food allergens: peanuts, tree nuts, fish, shellfish, soy & dairy
- Immune mediated include IgE & non-IgE antibodies
- Non-immune-mediated reactions are most common reactions (“food intolerance”)

# Latest Guidelines to Reduce Peanut Allergy

National Institute of Allergy and Infectious Diseases guidelines:

Introduce peanuts to infants who are approximately 6 mo old and have mild to moderate eczema.

Infants as early as 4 mo of age with severe eczema and/or egg allergy be “strongly considered” for peanut sensitivity testing.




# How Well Do We the Recommendations?

Among 60 health care professionals asked five questions based on NIAID peanut allergy guidelines:

Answered all five questions correctly



Answered four questions correctly



Healio<sup>★</sup>

Reference: Mehta P, et al. *Ann Allergy Asthma Immunol.* 2020;doi:10.1016/j.anai.2020.06.037.

## 6 Food Elimination Diet in Adults

No dairy, eggs, wheat, soy,  
peanut/tree nuts, fish/shellfish  
for 6 wks

Histologic response in 10/21  
responders

# Step-up Empiric Elimination Diet: 2-4-6

## Background

### Overall Efficacy

Elemental - 90.8%

SFED - 72.1%

Food Elimination - 45.5%



TFGED = 2 food group elimination diet

## Methods:

Prospective study conducted in 14 centers. Pts underwent a 6-wk 2-food-group elimination diet (TFGED: milk and gluten-containing cereals). Remission defined by Sx improvement and  $<15$  Eos per HPF

Non-responders were gradually offered a 4-food-group elimination diet (FFGED; TFGED plus egg and legumes) and a 6-food-group elimination diet (SFGED; FFGED plus nuts and fish/seafood)

In responders eliminated food groups were reintroduced individually, followed by endoscopy.

## Results:

130 pts (25 pediatric patients), 97 completed study phases

TFGED achieved EoE remission in 56 (43%) pts, age independent. Triggers in TFGED responders were milk (52%), gluten-containing grains (16%), and both (28%).

EoE induced only by milk was present in 18% and 33% of adults and children, respectively.

Remission rates with FFGEDs and SFGEDs were 60% and 79%, with increasing food triggers, especially after an SFGED. Overall, 55 (91.6%) of 60 of the TFGED/FFGED responders had 1 or 2 food triggers.

Compared with the initial SFGED, a step-up strategy reduced endoscopic procedures and diagnostic process time by 20%.

# Step-up Empiric Elimination Diet: 2-4-6

## Conclusions:

A TFGED diet achieves EoE remission in 43% of children and adults.

A step-up approach results in early identification of a majority of responders to an empiric diet with few food triggers, avoiding unnecessary dietary restrictions, saving endoscopies, and shortening the diagnostic process

# Immunotherapy for EoE

## Allergy Tests

Skin prick testing

Blood testing

- RAST - Radioallergosorbent
- ImmunoCAP
- ELISA - Enzyme-linked immunosorbent assay





# Allergy Test Directed Food Elimination Efficacy

- Low in Adults
- Variable in Children

# Immunotherapy for EoE

## Standard Subcutaneous Allergy Shots

- Limited data
- May benefit EoE pts with allergic rhinitis
- May be best in those sensitive to pollens containing allergens that cross react with food allergens
- Many of my patients seem to do well with SC Immuno-Rx



# Immunotherapy for EoE

- Sub-lingual Immune Therapy
  - FDA-approval of two directed at different grass pollen, one for dust mites and one for short ragweed
- Evidence shows that EoE can occur after oral/sublingual immunotherapy
- SLIT contraindicated for pts w EoE

# MC Rx for EoE

Prevalence of dysphagia in MCAS

58/175 MCAS pts (33.1%)

Prevalence of EoE in MCAS

2/175 MCAS pts (1.1%)

Limited experience in treating EoE with  
MC-directed therapy

# Summary - 1

- Prevalence of EoE is increasing and seems related to allergic epidemic
- EoE easily diagnosed by history, risk factors, biopsy, and endoscopy
- Must always diagnose food bolus obstruction cases – Bx (often not done)
- At least 6 biopsies often needed
- Lymphocytic esophagitis & Crohn's disease are in the DDx



## Summary - 2

- No superiority of different topical steroids
- EoE rapidly returns after cessation meds
- EoE best treated with 3 D's plus
- The PCP/Integrative physician can help with diet, compliance, and possibly by certain types of immune modulation.
- The PCP can refer dysphagia pts early